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SUMMARY   
In order to understand if a2-AMPK isoform is a friend or a foe in the protection of the 
myocardium against ischemia-reperfusion injury, we studied the functional consequence of its 
deletion on the contractility, the energetics, and the respiration of the isolated perfused heart 
and characterized the response to low flow ischemia and reperfusion. Alpha2 deletion did not 
affect basal contractility, respiration and high energy phosphate contents despite a 2 fold 
reduction in glycogen content and a 3 fold reduction in glucose uptake. Low flow ischemia 
(LFI) increased AMPK phosphorylation and stimulated glucose uptake and phosphorylation 
in both a2-KO and WT. The high sensitivity a2-KO to the development of ischemic 
contracture was attributed to the constitutive impairment in glucose transport and glycogen 
content and not a perturbation of the energy transfer by creatine kinase (CK). The functional 
coupling of MM-CK to myofibrillar ATPase and the CK unidirectional fluxes were indeed 
similar in a2-KO and WT. LFI impaired CK flux by 50% in both strains, suggesting that a2-
AMP does not control CK activity. Despite the higher sensitivity to contracture, the post 
ischemic contractility recovered to 60% of its control in both a2-KO and WT. This could 
partly result from a low cost of contractility in the a2-KO. In conclusion the a2-AMPK is 
required for a normal glucose uptake and glycogen content which protects the heart from the 
development of the ischemic contracture but it is not required for optimal post ischemic 
recovery of systolic activity in the absence of fatty acids.  
Key words: glucose uptake, energetics, rigor, creatine kinase, 31P NMR spectroscopy, 
energetic cost of contractility 
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Introduction  
AMPK is a major energetic sensor in the mammalian cell and regulator of cardiac 
metabolism, AMPK activation switches on the ATP synthesis pathways and inhibits the ATP 
consuming pathways (for recent reviews (14), (57). 
Despite numerous investigations, and as stated by (14) the question of “AMPK activation 
being an ally or an enemy in the protection against ischemic damage” is still controversial. On 
one side AMPK activation may be beneficial due to increased ATP production by stimulation 
of glucose uptake, glycogenolysis and glycolysis as well as fatty acid oxidation (14). As a 
result a chronic decrease in AMPK activity could induce energy deficiency and impair cardiac 
contractile function during an ischemia reperfusion challenge. However AMPK activation 
may be detrimental during post ischemic reperfusion due to the stimulation of fatty acid 
oxidation which inhibits glucose oxidation. It was indeed proposed that AMPK potentially 
contributes to post ischemic mechanical deficiency and reperfusion injury by uncoupling 
glycolysis from glucose oxidation (43): this would promote acidosis and could lead to 
overload the cell in sodium and calcium by sarcolemmal ionic exchanges. In this sense 
AMPK deficiency could be predicted to attenuate myocardial damage of the post ischemic 
heart. Activators of AMPK as AICAR are not fully selective, thus a knock out of the alpha2 
catalytic unit, the main cardiac a isoform is a model of choice for the study of the role of a2 
AMPK in the cardiac response to ischemia.   
The model of a2-AMPK knockout, a2-KO (55), results in complete abolition of the cardiac 
a2 activity without compensation by a1 isoform. In this mouse, a2 deletion accelerated the 
development of the ischemic contracture in global ischemia, but did not alter the post 
ischemic contractile recovery (58). An early rise in the ischemic contracture has already been 
observed in other transgenic models: the overexpression of dominant negative a2 kinase, DN 
(56) or the a2 kinase dead, KD, models (42). However, a major difference compared to our 
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accompanying study showing preserved contractile recovery (58), is the increased apoptosis 
and poor post ischemic contractility of the KD mutant which lead the authors to conclude that 
the activation of alpha2 AMPK plays an important protective role in limiting the damage of 
IR episodes.  
The myocardium depends for its contractility on the continuous adequacy in the flux of ATP 
synthesis, ATP transport (mainly by creatine kinase) and ATP utilization (mainly by the 
ATPases of the myofilaments and sarcoplasmic reticulum). The ischemic contracture results 
from the imbalance between the anaerobic ATP synthesis and ATP utilization which inhibits 
the myofibrillar ATPase activity by increasing ADP concentration (52), although calcium 
overload may contribute to its development (47). The ADP concentration is controlled at the 
level of myofibrils by the activities of the ATPase and of the MM Creatine kinase (MM-CK) 
bound to the myofibrils in its vicinity (52). Early rise in contracture can thus be related to a 
higher energetic requirement of the ATPases, to a decreased rate of glycolysis, to a decreased 
glycogen content or glycogenolytic flux, to an impaired transfer of energy by creatine kinase 
or to a defect in bound MM CK (15), (51). Because activation of AMPK by ischemia 
stimulates glucose transport at the sarcolemma and glycolysis by activation of 6-
phosphofructo-2-kinase (PFK2) leading to PFK1 stimulation (41), (35), the decreased in 
AMPK activation in the a2-KO might impair the stimulation of glycolytic ATP synthesis and 
be harmful to the myocardium.  
During early reperfusion, AMPK helps fatty acid oxidation to predominate over glucose 
oxidation. AMPK phosphorylates and inactivates acetyl-CoA carboxylase (ACC), decreasing 
the concentration of malonyl-CoA, the inhibitor of fatty acid transport into the mitochondria. 
In this sense the decreased activation of AMPK may be beneficial to the post ischemic 
contractile function.  
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Our aim was to characterize the consequences of a2-AMPK deletion on the basal and 
ischemic heart function and to investigate some of the mechanisms involved in its response to 
an ischemia reperfusion (I-R) insult. We chose the low flow ischemia (LFI) model which 
better simulates the conditions prevailing in an infracted region than global ischemia: during 
an acute occlusion of the left anterior descending coronary artery collateral flow still 
represents 10-40% of the baseline flow in the infarct zone. Pyruvate was used as substrate 
because its oxidation is efficient in LFI (33) and moreover as an antioxidant pyruvate allows 
to study the role of AMKa2 in conditions minimizing the complex and not fully understood 
interference of oxygen and nitrosyl radicals with AMPK activity. 
The consequences of a2 deletion on the contractility, oxygen consumption and energetics 
were firstly assessed in basal normoxic condition: we found uncompromised energetics and 
performance of the myocardium. In order to characterize the response of the a2-KO to low 
flow ischemia (LFI) and reperfusion we followed the time change of phosphorus metabolites 
and the stimulation of glucose transport and phosphorylation by LFI. Because Creatine Kinase 
(CK) has early been shown to be potentially regulated by AMPK activation both in vitro and 
in isolated skeletal muscle myofibrils (39); it could have been expected that AMPK deletion 
would alter its activity. However the deletion of a2-AMPK had no consequence on the global 
CK flux, measured by NMR magnetization transfer in normoxia, on the ischemic impairment 
of CK flux or on the function of MM-CK bound to myofibrils. Finally our results suggest that 
the maintenance of contractile performance of the a2-KO heart might be related to the lower 
energetic cost of its contractility. 
 
Methods  
Animals   
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Nine months old male a2 AMPK KO (-/-) and WT (+/+) were obtained by crossing 
heterozygote a2 AMPK (-/+) (55). The genotype of the offspring was checked by polymerase 
chain reaction PCR on DNA extracted from the tail. The animals were fed ad libitum a 
standard chow except for the estimation of glucose transport and phosphorylation in which the 
animals were fasted for 12 to 18 hours. The investigation was conducted in accordance with 
our institutional guidelines defined by the European Community guiding principles in the care 
and use of animals and French decree no. 87/848 of October 19, 1987. Authorizations to 
perform animal experiments according to this decree were obtained from the French Ministry 
of Agriculture, Fisheries and Food (no. 7475, May 27, 1997). 
 
Perfused heart  
Mice were anesthetized by intraperitoneal injection of urethane (2 mg/g). The heart 
dissection was performed in a solution containing low Calcium (0.4mM) and high glucose 
(15mM). The perfusion solution contained (in mM): Na 143; K 6; Ca 1.8; Mg 1; mannitol 1.1; 
Hepes 20, glucose (11 mM) and pyruvate (2 mM) and was oxygenated with 100 % O2. pH 
was adjusted to 7.35 at 36.5 °C. Hearts were perfused at a constant flow of 2.5mL.min-1 the 
average flow value measured in the same hearts perfused at a constant pressure (see  (58). To 
ensure adequate oxygenation and thermoregulation the silicon perfusion line was surrounded 
by circulating water continuously bubbled with 100% O2 at 36.5°C down to the heart. A latex 
balloon inserted in the left ventricle chamber was inflated to maximal isovolumic condition of 
work (end diastolic pressure of 5-8 mmHg). The on-line measured parameters were heart rate 
(HR, in beats.min-1), left ventricle systolic developed pressure (LVP), end diastolic pressure 
(EDP), coronary pressure (all pressure expressed in mmHg). Contractility was estimated as 
the rate pressure product (RPP, expressed in 104.mmHg.beats.min-1). Hearts were freeze 
clamped to measure their ATP, Phosphocreatine (PCr) and glycogen contents (in 
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nmol.mg.prot-1) and to assess the state of AMPK phosphorylation at the end of control, LFI 
and reperfusion periods. 
 NMR spectroscopy  
31P NMR spectra were acquired on a Inova Varian at 9.4 T wide bore magnet in 10 
mm diameter tubes using a 80° pulse angle f, 4 K data points acquisition, a spectral width of 
10000 Hz, an acquisition time of 0.205 s, a repetition time of 2s, 32 scans, zero filling to 8 K 
and line broadening of 30 Hz. After 10 min of equilibration, 4 partially saturated spectra and a 
fully relaxed spectra (repetition time 10s) were acquired. Stability of the preparation was 
checked by comparing control spectra acquired before and after the magnetization transfer 
experiment: any heart showing more than 10 % variation in its metabolite content was 
discarded. In a pilot study we found the kinetics of depletion of PCr during global 
normothermic ischemia to be too fast for accurate detection and PCr content to low to allow 
the determination of CK flux. WT and KO hearts, freeze clamped in control, showed similar 
ATP contents measured by spectrofluorimetry, the average ATP content, (19.0 ± 0.5 nmol.mg 
prot-1 , n=10) was used as a reference for the NMR quantification of PCr, Pi and 2DG6P 
concentrations after correction for incomplete magnetic relaxation as described previously 
(23). A cytosolic water volume of 2.72 µL. mg. protein-1 was used to calculate the 
concentrations. Free cytosolic ADP was calculated from the equilibrium of CK (apparent 
equilibrium constant KeqCK= 166. 10-0.87(pH-7)). Free AMP concentration was [AMP] = 
[ADP]2. KeqAK/[ATP] (using the adenylate kinase equilibrium constant KeqAK=1.05 (31) and 
the free energy of ATP hydrolysis was A ATP = A0 +RT ln [ATP]/[ADP].[Pi].   
 
Kinetics of Creatine kinase  
CK forward flux (PCr? ATP) was assessed by Time Dependent Saturation Transfer 
(TDST) of gATP under control as previously described (6), [(49). Briefly 24 scans fully 
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relaxed spectra repetition time =10s) were acquired by blocs of 8 scans cycling 3 times 
through the whole protocol. Six spectra acquired with gATP saturation (duration 0 to 4s) 
allowed measuring the PCr relaxation time, T1PCr and the apparent rate constant kfor of the CK 
reaction. The average control T1PCr values were similar in both groups (3.1 ± 0.5 and 3.2 ± 0.4 
s in WT, n=12 and KO, n=11 respectively). To reduce experimental time and because T1PCr is 
unchanged by low flow ischemia, steady state saturation of gATP was applied in low flow 
ischemia. kfor was determined from the ratio Mss/Mo= 1/[1+kfor T1PCr)]  (Mss and Mo were 
the magnetization of PCr in the presence and absence of a 4s saturation of gATP, T1PCr = 
3.1s). CK forward flux, the product of kfor and PCr concentration, was expressed in mM.s-1. 
Glucose transport and phosphorylation was assessed by following the transport and 
phosphorylation of 2-D-deoxyglucose (2DG, 5mM) in presence of pyruvate (5mM). Inorganic 
phosphate (1mM) was added to the perfusate to prevent phosphorus depletion occurring in 
this protocol. After 25 min of control perfusion, 2DG was infused and the rate of apparition of 
2-Deoxy-D-glucose-6-phosphate (2DG6P) was assessed during 15min (7 spectra)  
 
Low flow Ischemia protocols  
After 10 min of equilibration in isovolumic condition of work, the stability of 
metabolite content was checked for 15 min and CK flux assessed by TDST followed by 2 
control spectra. Low flow ischemia was induced by reducing flow to 10% of its control 
(LFI10) for 30 min to assess the time change of phosphorus metabolites and pHi. Metabolic 
steady state was reached after 12min of LFI10 and CK flux measured by SSST followed by 2 
control spectra. Some of the hearts were freeze clamped to estimate AMPK phosphorylation. 
Flow was further reduced to 5% of control (LFI5) for 15 min and restored to its control value 
for 35 min (R: reperfusion) before freeze clamping (KO, n=6; WT, n=6). For the 
determination of ischemic glucose transport and phosphorylation, the same hearts used to 
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determined control 2DG6P accumulation were submitted to LFI10 for 25 min (10 spectra) to 
assess ischemic stimulation in each individual heart. 
   
Respiration and energetic yield  
Oxygen consumption (QO2) was measured in parallel experiments out of the magnet using the 
same LFI reperfusion protocol. QO2 was measured on line from the difference in oxygen 
content in incoming (aortic PaO2) and outgoing (pulmonary artery, PvO2) perfusate using 
oxymeters (Stratkhelvin Inst., Glasgow) and Clark electrodes equipped with fast O2-
permeable membranes in thermoregulated chambers. QO2 was expressed in µmoleO2.min-1.g 
WW-1. The energetic yield was estimated by analyzing the relationship of steady state QO2 to 
RPP in the same protocol of ischemia-reperfusion (WT, n=6; KO, n=6). To assess a wider 
range of contractile performance, a group of 6 WT and 6 KO hearts was submitted to beta 
stimulation by stepwise increases in isoprenaline concentrations (namely [ISO] = 10-10M, 10-
9M, 3.16.10-9M, 10-8M, 3.16.10-8M and 10-7M ). This group was perfused under constant 
pressure (75mmHg) at a lower external Ca concentration (Cao=1mM) to prevent calcium 
overload and fibrillation. Coronary flow was continuously measured by a T106 flowmeter 
equipped with a 1N probe (Transonic System Inc, Ithaca, NY USA). Steady state values of 
RPP and QO2, obtained 10 min after the change in [ISO], were used to estimate the energetic 
yield by the linear regression between QO2 and RPP  
 
Intrinsic contractile properties of myofilaments  
Mouse hearts were perfused under control condition (n= 4) or submitted to 10 minutes 
global ischemia after stabilization (n=4). Muscle fiber bundles were dissected from LV 
papillary muscles in a relaxing solution (pCa= -log 1/[Ca] = 9, see solutions below), incubated 
for 45 min at 4 °C with 1% Triton X-100 to solubilize the membranes and transferred to 
H
AL author m
anuscript    inserm
-00151019, version 1
. . - 10 - 
relaxing solution at 4 °C until use. For ischemic fibers preparation and experiments, the 
solutions contained okadaic acid (100 nM) to inhibit phosphatases. After connection to a force 
transducer (model AE 801, SensoNor Microelectroniks), sarcomere length was adjusted to 
slack length and stretched by 20%. All experiments were performed at 22 °C. Solutions, 
prepared as previously described (52), contained (in mM): EGTA: 10; imidazole: 30; Na+: 
30.6; Mg2+, 3.16; dithiothreitol: 0.3. Ionic strength was adjusted to 0.16 M with potassium 
acetate, and pH to 7.1 with acetic acid. Relaxing solutions contained MgATP: 3.16 mM, PCr: 
12 mM pCa: 9. Activating solutions contained same metabolites and pCa ranged from 9 to 4: 
active force and sensibility to Ca was determined under isometric conditions by stepwise 
decrease in pCa until maximum tension was reached. Rigor solutions contained ATP ranging 
from pMgATP 6 to 2.5 at pCa 9. Rigor force and sensitivity to ATP were assessed by 
stepwise decrease in pMgATP while MM CK functional activity was assessed by the same 
protocol in the presence of PCr 12mM to activate myofibrillar bound CK.  
Tension was expressed in mN.mm-2 and data were fitted using a nonlinear fit of the 
Hill equation (Microcal Origin software, version 6.0).  
 
Expression and phosphorylation of AMPK  
 Freeze-clamped hearts were kept in liquid nitrogen until their homogenization in a 
lysate buffer containing TRITON X-100: 0-1 %,  and in mM HEPES: 50, KCl: 50, EDTA: 1, 
EGTA: 1, beta-glycerol-phosphate: 5, orthovanadate: 1, DTT: 1, NaPPi: 5, PMFS: 2, and a 
cocktail of protease inhibitors (Calbiochem Set V EDTA free). Fifty µg of protein were used 
for western blotting detection of AMPK isoforms using the polyclonal Phospho-AMPK-a 
(Thr172) and AMPK-apan, antibodies (Cell Signaling) diluted at 1:500 and 1:1000 
respectively. Samples were resolved by 8% SDS-PAGE, transferred to PVDF membranes 
which were blocked with 3% skimmed milk and then probed overnight at 4°C with the 
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antibody. HRP conjugated-donkey anti-rabbit secondary antibody (Santa Cruz) was used for 
further detection by enhanced chemiluminescence (AMS). Sample loading was confirmed by 
Coomassie dying of the gel after the transfer process. Quantification of signals was performed 
using the Quantity-One software from Bio-Rad and arbitrary units were standardized by 
loading a standard sample in every separated gel. For Glut1 and Glut4 detection, 20 µg of 
protein of total conventional extracts were probed with polyclonal anti Glut1 and Glut4 
antibodies (Chemicon) diluted at 1:1000. 
 
Statistical analysis 
All results are shown as mean ± sem. T test was used to compare WT and a2-KO. 
Variance analysis followed by a Student Newman Keuls test was used to compare control, 
LFI and reperfusion in each group. A value of p< 0.05 was considered as significant.    
 
RESULTS 
Cardiac phenotype function and energetics of the a2-KO hearts  
As also found in younger mice (58) deletion of the a2 subunit did not modify the 
expression of a1 protein, the a2 subunit was not detectable and the total AMPK protein level 
was reduced by about 60% (not shown) in agreement with the known cardiac distribution of 
a-isoforms. The characteristics of the animals were similar and no sign of cardiac hyper- or 
hypotrophy was found in the a2-KO old mice (Table 1A) Thus, aging did not reveal 
morphological consequences of the a2AMPK deletion in contrast with other transgenic 
models (36),. 
 
The contractile parameters, left ventricular developed pressure (LVP), heart rate (HR), 
rate pressure product (RPP) and the coronary pressure were similar in AMPK KO and WT 
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hearts (Table 1 B). The energetic status of the a2-KO did not differ from that of the WT heart 
(Table 2), although a slight non significant reduction in PCr could be observed in the former. 
ATP, Pi, pHi, as well as the calculated indexes: free ADP and AMP concentrations and the 
free energy of ATP hydrolysis (-AATP) were similar in both strains. Oxygen consumption 
(QO2) was also similar both under constant flow or constant pressure perfusion conditions 
(see further). However glycogen content was about two fold lower in the a2-KO than in the 
WT. This shows that, apart from decreasing the glycogen reserve, the deletion of the a2 
catalytic subunit had no major effect on the normoxic contractile respiratory and energetic 
status.   
 
Contractile and metabolite changes in low flow ischemia and reperfusion 
The acceleration of the global ischemic contracture reported in the accompanying 
paper in the a2-KO could result from a defect in the anaerobic ATP synthesis pathways 
(glycolytic or glycogenolytic), and/or in the energy transfer or buffering by creatine kinase. 
Indeed both events inhibit the myofibrillar ATPase activity by increasing ADP concentration 
(52). To understand the factors contributing to the acceleration of the ischemic contracture we 
used a model of partial ischemia, reducing flow to 10% (LFI10) and then to 5% (LFI5) of its 
control value, and followed the time course changes in phosphorylated compounds and pHi in 
WT and KO hearts. The immediate drop in RPP induced by LFI10 (resulting from both 
decreased LVP and HR, not shown) was similar in WT and a2-KO (Fig. 1). The end diastolic 
pressure rose in 4 out of 9 a2-KO heart but in none of the WT heart. Due to the variability of 
EDP rise in the a2-KO heart, the average EDP during moderate LFI10 was not significantly 
different in both groups.  
In terms of phosphorus compounds, the onset of LFI10 resulted in an immediate drop 
in [PCr] followed by the establishment of a new steady state after about 10 min (allowing to 
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measure CK flux, see further). Steady state [PCr] was not significantly different in a2-KO and 
WT (Fig. 1), although its percent decrease was less pronounced in the a2-KO (down to 38 ± 
5% and 55 ± 4 %, p<0.05 respectively, Fig. 2). [ATP] decreased monotonously to about 70% 
of its control value in both strains and a similar moderate acidosis occurred (pHi was 6.87 ± 
0.05 in KO and 6.91 ± 0.09 in WT, ns). Despite these discrete changes, the PCr to ATP ratio 
was less affected by ischemia in KO than in WT (1.38 ± 0.05 and 0.92 ± 0.09, respectively p 
<0.001) and thus the free [ADP] increased largely in WT (146 ± 21 µM) compared to a2-KO 
(82 ± 6µM, p<0.01, Fig. 2). Free AMP rose about 2 fold in a2-KO compared to 12 fold in WT 
(to 1.4 ± 2 µM and 4.4 ± 0.9 respectively p<0.01) The free AMP to ATP ratio increased by 3 
fold and 17 fold, respectively. The glycogen content measured at the end of LFI10, was 
significant lower in a2-KO than in WT (3.4 ± 0.8 and 9.7 ± 1.5 µmol glucosyl unit.gFW-1, 
p<0.01). Due to remnant pyruvate oxidation, glycogen depletion was modest and the rate of 
its utilization appears similar in both groups (about 0.12 µmol glucosyl unit. gFW-1. min-1).  
To increase the metabolic challenge, flow was further reduced to 5% of control (LFI5). 
A significant ischemic contracture developed in all a2-KO hearts but only in one of the WT: 
the average EDP rose by 28 ± 8 and 5 ± 2 mmHg respectively at the end of the 15min LFI5 
period, (p<0.05 , Fig. 1). Metabolic changes were exacerbated in both a2-KO and WT: lower 
[ATP] and pHi occurred in a2-KO (Fig. 1 and 2). As for moderate LFI10 ischemia, both the 
accumulation of ADP and AMP as the increase in AMP to ATP ratio were modest in the a2 
KO compared to the WT heart (Fig 2). For example free [AMP] rose to 1.8 ± 0.2 µM in a2-
KO vs 6.7 ± 1.6 µM in WT (p<0.01). The lower global adenylate content observed in the a2-
KO, suggests the existence of a larger cellular efflux of adenylate moieties probably 
contributing to the lower ADP and AMP concentrations of the a2-KO heart.  
Upon reperfusion EDP further rose in both strains. Despite the exacerbation of 
ischemic contracture, post ischemic systolic activity recovered to similar levels in both a2-KO 
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and WT (to about 60% of control, Fig. 1). ATP recovery was insignificant, as expected from 
the leakage of purine bases occurring during ischemia and from the slow rate of purine 
biosynthesis in the myocardium. The time course of PCr and pHi recovery appeared slower in 
a2-KO than in WT. At the end of reperfusion period, the ATP concentration, the sum of 
adenylates and pHi were significantly lower in a2-KO than in WT and did not recover to their 
control value in a2-KO. AMP recovery was complete in both strains. The ischemia-recovery 
protocol (I-R) induced similar leakage of cytosolic enzymes (LDH and AK) in both strains 
while the mitochondrial citrate synthase activity was unchanged (Table 4).  
 
Creatine kinase activity and flux 
To understand if alterations of creatine kinase fluxes participate in the early 
development of contracture, CK function was evaluated. The specific activity of the enzymes 
involved in energy transfer (CK, and adenylate kinase, AK) was unaltered by the a-2 deletion 
(Table 4). The unidirectional forward CK flux (PCr à ATP) was measured by 31P NMR 
saturation transfer in control and LFI10 (Fig. 3A). In control, the apparent rate constant kf and 
the CK forward flux were similar in a2-KO and WT (average CK flux ca. 8.5mMole.s-1). 
LFI10 induced a similar 50% impairment of CK flux in both strains. The decrease in CK 
specific activity was expected from the well known leakage of cytosolic CK at reperfusion 
(Table 4). Thus the deletion of the a2-AMPK did not no alter global control and ischemic CK 
fluxes, suggesting that the regulation of CK is not critically dependent on the presence of 
a2AMPK isoform or on the ischemic stimulation of AMPK activity.  
However, the preservation of global CK flux does not imply unaltered subcellular CK 
function (24). Indeed the function of the MM-CK isoform bound to the myofilaments controls 
the local ADP concentration responsible of the formation of rigor bonds in ischemia (53). 
Because AMPK co-localizes with MM-CK in myofibrils and was early suggested to control 
H
AL author m
anuscript    inserm
-00151019, version 1
. . - 15 - 
its activity by phosphorylation (39), the absence of the a2-isoform could directly affect the 
rigor properties of the myofibrils. The consequence of the a2 deletion on the activity of MM- 
bound CK and the rigor properties of the myofibrils were assessed in triton-skinned fibers 
isolated from normoxic or ischemic perfused hearts. Figure 3B shows the rigor force induced 
by decreasing MgATP concentration and the sensitivity to ATP, (characterized by 
pMgATP50: the pMgATP inducing half rigor force development). The sensitivity to ATP of 
the rigor force was unaffected by a2-deletion (pMgATP50 was similar in WT and KO, Table 
4). An index of the functional activity of MM CK activity bound in the vicinity of the ATPase 
is the shift in the apparent pMgATP50, induced by addition of PCr (54). The addition of PCr 
induced a similar shift of pMgATP50 in WT and a2-KO (fig 3B, Table 4) showing that the 
absence of a2 AMPK did not modify the functional activity of myofibrillar bound CK. 
Contractile properties of fibers isolated from ischemic WT and a2-KO were similar to those 
of their normoxic control (not shown). In conclusion our results show that the acceleration of 
the ischemic contracture in the a2-KO is not due to an inhibition of the energy transfer and/or 
buffering by CK or to an alteration of the function of MM-CK bound in the vicinity of 
myofibrils.  
 
Glucose uptake and phosphorylation  
Because AMPK, as a metabolic switch, is involved in the control of glycolytic 
activation under stress, we assessed the consequence of a2 deletion on glucose transport and 
phosphorylation by following the phosphorylation rate of 2-deoxy-D-glucose by 31P NMR 
spectroscopy in control and under LFI10. Figure 4A presents a series of spectra obtained from 
representative WT and a2-KO hearts perfused at normal flow before (spectrum a) and various 
time after the addition of 2DG 5mM (spectra b, c, and d). In control flow, the accumulation of 
2DG6P was 3 fold slower in a2-KO than in WT (0.2 ± 0.1 and 0.6 ± 0.1 nmol.min-1.mg prot-1 
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respectively p<0.05, Fig. 4B). Each individual heart was then subjected to 15 min of LFI10. 
The rate of 2DG6P accumulation increased in both strains albeit to a lower level in a2-KO 
than in WT (0.6 ± 0.2 and 1.5 ± 0.2nmol.min-1.mg prot-1, respectively p<0.01). Notice 
however that the 3 fold ischemic stimulation of 2DG transport and phosphorylation was 
similar in both mice (Fig. 4B). The defect in glucose transport and/or phosphorylation in the 
control a2-KO is not due to a reduction in the expression of glucose transporters Glut 1 and 
Glut4 (Fig. 4C). Thus, the a2 AMPK isoform is required for a normal glucose uptake and 
glycogen content under normoxic condition although the stimulation of glucose uptake 
occurring during ischemia seems to be independent on the presence of the a2 isoform. In 
conclusion both the impaired glucose transport and phosphorylation and the low content in 
glycogen could account for the early rise in ischemic contracture of the heart deleted in a2-
AMPK.  
 
Phosphorylation of AMPK  
Figure 5A shows western blot of total AMPK and AMPK phosphorylated in WT and 
a2-KO hearts under control condition as well as the stimulation of phosphorylation by LFI10  
(both in the presence or in the absence of 2DG). In control condition, a very low basal 
phosphorylation of total AMPK was found in a2-KO compared to WT. Low flow ischemia 
(LFI10) significantly increased AMPK phosphorylation in both a2-KO and WT (Fig. 5C). 
However phosphorylation of AMPK by LFI10 was 3 fold lower in a2-KO than in WT and 6 
fold lower in LFI in the presence of 2DG. Upon reperfusion, AMPK phosphorylation 
decreased in both strains, remaining slightly higher than control in the a2-KO. 
 
Energetic cost of contraction  
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To understand how the contractility of the a2-KO heart can be similar to that of a WT, 
we assessed their energetic cost of contraction. Indeed one of the strategies of the 
myocardium submitted to a chronic stress is to improve the economy of its contraction 
(44).The oxygen consumption (QO2) was continuously measured in a protocol of LFI-
reperfusion performed out of the magnet (Fig. 6A). Contractile response, RPP and rise in 
EDP, were similar to those described in Fig. 1. QO2 in basal condition although slightly lower 
in a2-KO was not significantly different from WT (5.1 ± 0.4 and 6.6 ± 0.6 µmolO2. min-1. 
gWW-1, respectively). QO2 during LFI10, LFI5 and reperfusion were also similar in both 
strains. The energetic cost of contractility (estimated by the slope of the relationship between 
QO2 and contractility) tended to be lower in a2-KO than in WT, but the difference did not 
reach significance. To analyze more precisely this relationship, higher contractile 
performance was induced by ß-stimulation. Because perturbation of the urinary excretion of 
catecholamines was previously described in this model (55), we first verified that the a2 
deletion did not alter the response of the myocardium to catecholamines. The sensitivity to 
isoprenaline (ISO) was similar in both strains as shown in Fig. 6 B (pooled value of EC50 = 
4.9±0.5 .10-9M ISO). Maximal stimulation, obtained in presence of 3.10-8M ISO, resulted in 
non statistically different values of RPP (10.3 ± 0.7 and 8.3 ± 0.8 104 mmHg.beat.min-1 in a2-
KO and WT respectively) and QO2 (18.5 ± 2.9 and 20.5 ± 2.5 µmolO2. min-1. gWW-1). Thus, 
the a2-KO perfused in presence of glucose and pyruvate was not limited in its energy 
production. However, the energetic cost of contraction, estimated from the slope of the linear 
relationship between oxygen consumption and RPP was significantly lower in a2-KO than in 
WT (Fig. 6 C, see legend for details). This favors the hypothesis that the a2-AMPK deletion 
induced an improvement in the economy of contraction  
In order to improve the economy of its contraction, a rodent heart under chronic stress 
expresses slow isoform of myosin-ATPase, which consumes less ATP per force unit, or might 
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change the activation properties of its ATPase. The isomyosin profile of the WT, shows a 
pure V1 phenotype (100% fast type, WT n=9) as expected in a mouse heart, and this profile 
was unaltered by the a2-AMPK deletion (a2-KO n= 8). The active tension and the calcium 
sensitivity of the ATPase studied in triton skinned fibers are shown in Table 4. Both the 
maximal active tension of myofibrils (at pCa 4.5) and the sensitivity of myofibrillar ATPase 
to calcium activation were similar in a2-KO and WT (the half activation, pCa50, was 5.64 ± 
0.03 in a2-KO and 5.55 ± 0.03 in WT, ns). In conclusion the improvement in the economy of 
contraction observed in a2-KO did not result from adaptations of the contractile machinery.  
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DISCUSSION 
 
The basal cardiac energetic status, contractility and respiration are unaffected by a2-
AMPK deletion. We found a dual effect of the a2 AMPK deletion on the contractile and 
metabolic response of the myocardium submitted to a low flow ischemia-reperfusion episode. 
We confirm that the a2 AMPK is more susceptible to the development of an ischemic 
contracture. We show that this acceleration of contracture can be explained by a deficit in 
energy synthesis resulting from both a constitutive impairment of glycogen stores and a 
decreased glucose uptake and phosphorylation and not by an impairment of energy transfer. 
The unaltered energy transport by creatine kinase and function of the MM bound CK, suggest 
that the a2 AMPK does not control creatine kinase in the myocardium. A novel finding is that 
the a2-AMPK deletion does not alter the post ischemic contractile function of an isolated 
heart perfused in presence of glucose and pyruvate.  
 
Contractility and energetics of the normoxic heart 
Despite the 3 fold decrease in glucose uptake and phosphorylation observed in 
presence of pyruvate (Fig. 4), the a2 AMPK deletion did not induce contractility defect as 
also observed ex vivo and in vivo in the same transgenic model (58). This shows that the 
presence of a2-AMPK isoform is needed for optimal normoxic glucose transport and 
phosphorylation, although it is not required for the expression of glut transporters (Fig. 4). 
The similarity of the energy status of the a2-KO and WT heart indeed shows that the balance 
of energy utilization and synthesis is unaffected by a2 deletion: thus the a2-KO heart is not an 
energetically starved myocardium. One could argue that the contractility of the isolated 
isovolumic perfused heart is low compared to the condition prevailing in vivo. However 
steady state high levels of contractility (similar to that of a WT heart) can be supported even 
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at maximal level of ß-stimulation when pyruvate and glucose are available (Fig. 5). A novel 
interesting observation is that the a2-deletion induced an increase in the economy of 
contraction. We showed that this does not result from the usual strategies developed by the 
pathological rodent heart which tends to reduce the cost of its myofibrillar ATPase by 
expression of a slow type myosin. Thus the a2-AMPK is not involved in the expression of 
myosin or regulatory contractile proteins (as suggested by the similarity of Ca sensitivity of 
the myofibrillar ATPase). Further investigation is needed to understand if the economical 
contraction of the a2-KO results from a modification in Ca homeostasis, in excitation 
contraction coupling and/or in mitochondrial efficiency. 
 
Alpha2 AMPK protects the heart from the ischemic contracture  
LFI differs from global ischemia in two major ways. Degradation products (mainly 
lactate, protons, adenosine…) are washed out of the cell enabling continuation of glycolytic 
ATP production. Besides, due to the remnant oxygen supply, mitochondrial substrates 
oxidation still occurs: even at very low flow (down to 3% of control), as much as a third of 
the total ATP production originates from oxidative metabolism (33). Thus, both glycolytic 
and oxidative ATP supplies concur to less severe bioenergetics defect in LFI than in global 
ischemia which results in cessation of contractility, huge rise in end diastolic pressure and 
drastic changes in high energy phosphates. A 30 minutes period of flow restriction down to 
10% induced a moderate decrease in PCr, ATP, and pHi (as previously reported in the rat 
heart (9) and rapidly resulted in a new metabolic and contractile steady state in both WT and 
a2-KO. The increased susceptibility for the development of an ischemic contracture observed 
in global ischemia (see (58)) was also evidenced in the low flow model (Fig. 1A): EDP rose 
in the a2-KO hearts and hardly in WT. The development of the ischemic contracture results 
mostly from an imbalance of the energy homeostasis leading to accumulation of ADP at the 
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level of myofibrils, inhibition of ATPase and development of a rigor state (52). Neither the 
sensitivity of myofilament to ATP nor the efficacy of bound creatine kinase was altered in 
a2-KO. In this model calcium overload may contribute to the development of the contracture 
(47), the Ca homeostasis was not assessed in the a2-KO hearts, thus a perturbation in the 
activity of the Na, Ca and proton sarcolemmal exchanges or of the sarcoplasmic reticulum 
(SR) Ca ATPase, can not be excluded. Indeed the abundance of glycogen in the vicinity of 
SR, and the requirement of glycogenolytic and glycolytic activities for optimal SR function 
(7) suggest that the consequence of the glycogen deficit on the SR function in the a2-KO is an 
interesting field to be studied.  
The imbalance in energy homeostasis can result from an increased energy demand, an 
impairment of energy transfer by creatine kinase and/or a deficit in the anaerobic ATP 
synthesis pathways. The hypothesis of an increased energy demand is eliminated by the 
similarity of LFI contractility in a2-KO and WT (Fig. 1 and 6 A) and the absence of change in 
the intrinsic contractile properties of the myofibrils (Table 4). The similarity of ischemic 
creatine kinase fluxes (Fig. 3A) eliminates the hypothesis of a deficit in energy transfer by 
CK. On the contrary, because AMPK has earlier been suggested to inhibit CK activity (39), 
lower phosphorylation of AMPK in the ischemic a2-KO could have been expected to prevent 
the ischemic decrease in CK flux. This was not observed (Fig. 3A). Thus, provided the a1 
isoform is not specifically implied in the regulation of CK flux, our results showed that the 
inhibition of CK by AMPK in the ischemic cardiac cell is of a minor physiological 
importance compared to other factors known to decrease global CK flux as for example 
acidosis or impairment of mitochondrial CK flux (18), (24).  
Surprisingly, LFI induced in the alpha2 KO a high steady state PCr to ATP ratio which 
prevented a major free ADP (and AMP) rise in LFI10. This could have resulted from an 
unbalanced subcellular CK fluxes. However this hypothesis is not supported. Neither the 
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expression of MM, MB, BB or mitochondrial isoform of CK, nor the coupling of MM-CK to 
myofibrillar ATPase (Fig. 3) or that of mito-CK to adenine nucleotide translocase (3) were 
altered by the a2 AMPK deletion. The ischemic free ADP and AMP concentrations, besides 
being controlled by CK and AK activities, also depend upon the activity of the enzymes of the 
AMP degradation pathways (AMP deaminase and 5’-nucleotidase). Except in global 
ischemia, in which the degradation products can not be extruded from the cell, an inhibition of 
respiration (by hypoxia, chemical inhibition or LFI) rapidly releases purine bases in the 
cardiac effluent. This results from AMP hydrolysis and rapidly follows the initiation of ATP 
depletion (10), (19). This mechanism is thought to be beneficial in short term hypoxia (28). 
The sum of adenylates (ATP+ADP+AMP) was indeed significantly lower in a2-KO than in 
WT at the end of LFI (4.4 ± 0.4 vs 6.4 ± 0.4 mM, p<0.01).This suggests that the low ADP and 
AMP concentrations found in the a2-KO (Fig. 2) might result from an increase in the 
degradation pathways. It is thus an interesting possibility, which to our knowledge has not 
been explored yet, that the a2 AMPK subunit might interfere with the regulation or the 
expression of enzymes involved in the AMP degradation pathways.  
 
Thus in the absence of alteration in energy utilization and transfer, the energetic 
imbalance mostly results from a deficit in energy synthesis. Indeed both a decrease in 
glycolytic and in glycogenolytic ATP production accelerate the low flow ischemic contracture 
in the rat heart (12). A major deficit in the basal glycogen content of the a2-KO was observed 
(Table 2 and by (58)). As discussed in the accompanying paper, because the AMPK glycogen 
binding domain plays a critical role in glycogen storage, the deficit in ß2-subunit of AMPK, 
together with decreased glucose uptake most probably contribute to the impaired glycogen 
storage of the a2-KO. Indeed the deficit in glycogen storage, rather than in its rate of LFI 
utilization, is involved in the early development of contracture (Fig. 4). Similar results were 
H
AL author m
anuscript    inserm
-00151019, version 1
. . - 23 - 
observed in the KD mutant while unaltered glycogen stores but a reduced ischemic 
mobilization was found in the DN mutation (42), (56). The increase in glucose transport being 
a primary component of the glycolysis stimulation by ischemia, the slower glucose transport 
and phosphorylation in LFI (Fig. 4) as well as the marked decrease in lactate production 
found in global ischemia (58) shows that the a2 deletion impairs anaerobic glycolysis. As 
ischemia was still able to stimulate glucose uptake in a2-KO (Fig. 4B), the a2 isoform is not 
required for the ischemic stimulation of glucose transport and phosphorylation and the a1 
isoform is responsible for this remaining stimulation. This again differs from the model of DN 
over expression model, where the inactivation of a2 did not affect basal 2DG but blunted its 
ischemic stimulation (56). In conclusion, the decreased glycogen stores, the impaired glucose 
transport and/or phosphorylation both concurring to impaired anaerobic ATP synthesis in the 
a2-KO myocardium, show that the presence of a2 AMPK is essential for the prevention of 
ischemic contracture.  
 
a2 deletion does not impair ischemic and  post ischemic contractility  
We deliberately choose to use pyruvate as substrate because its oxidation is efficient in 
LFI, it enhances cardiac efficiency and also acts as an antioxidant (33), (34). In term of fuel 
utilization, pyruvate increases the activity of complex II and that of complex I by anaplerotic 
flux via oxaloacetate. Moreover, through its conversion to lactate, pyruvate could relieve 
glycolytic constraint due to NADH accumulation under ischemia (5). The antioxidant effect 
of pyruvate is well documented: exogenous pyruvate carboxylation produces citrate, citrate 
generating NADPH, maintains the glutathione system redox state in LFI (33),(34). Indeed 
pyruvate was shown to prevent cardiac dysfunction and AMPK activation induced by 
hydrogen peroxide in the isolated rat heart (32). Thus, pyruvate, by reducing the 
consequences of free radical production occurring massively at reperfusion, allowed the study 
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of the role of a2-AMPK isoform in conditions that minimize the complex interference of 
oxygen and nitrosyl radicals with AMPK activity.  
A major novel observation is that, despite the acceleration of the ischemic contracture, 
the a2-AMPK deletion did not exacerbate the contractile consequences of an ischemia 
reperfusion episode in the heart perfused with glucose and pyruvate. At first sight surprising, 
such dichotomic effect has already been reported. Indeed, although the concept as been on 
debate for a long time, the ischemic contracture is not a good predictor of the postischemic 
recovery. For example, post ischemic contractility is improved, despite an acceleration of the 
development of contracture by preconditioning and depletion of glycogen stores (25), (26), 
(12). Our results are in the same line: the a2 AMPK deletion decreased glycogen, accelerated 
the contracture, while it did not affect postischemic contractile recovery albeit the depletion in 
ATP content. It must be mentioned that, although ATP depletion has been used as a predictor 
index of heart insult in vivo (38), there is no causal relationship between ATP depletion and 
contractile activity (37), (23), (4). Such dissociation is also shown here: the contractile 
recovery of the a2-KO was normal despite its lower ATP content. In fact, the ATP 
concentration (around 4 mM) is sufficient to fully activate the ATPases because it is still 103 
fold higher than their Km for ATP. Indeed contractility depends on the turnover fluxes of 
ATP and not on its concentration (37), (4), (49). Thus despite a lower energetic status at 
reperfusion, the similarity of post ischemic contractility in a2-KO and WT suggests similar 
recovery of ATP turnover. This is most probably related to the low cost of contraction in the 
a2-KO. Because the isomyosin profile and the regulation by calcium of the active tension 
were similar in a2-KO and WT hearts this economical contraction does not originate from a 
lower ATP requirement of the myofibrillar ATPase but rather from an improvement in the 
ATP generating steps. Several mechanisms could contribute to the higher efficiency of the 
mitochondria in a2-KO. A shift in endogenous substrate utilization could increase the P/O 
H
AL author m
anuscript    inserm
-00151019, version 1
. . - 25 - 
ratio or the intrinsic properties of mitochondrial respiration could be altered (3). Besides, 
because AMPK activation upregulates the uncoupling protein (UCP) in skeletal muscle (59), 
one can not currently exclude that the chronic impairment of AMPK activity could decrease 
UCP expression in the a2-KO myocardium. Such mechanism would promote ATP synthesis 
because the activation of UCP at the onset of reperfusion increases QO2 at the expense of 
ATP synthesis (22). Finally, because high adenosine levels improve the economy of 
contraction (20), the depletion in adenylate in the ischemic a2-KO could increase coronary 
adenosine and contribute to its low cost contractility. Further work is required to test the 
origin of the mitochondrial efficiency of the a2-KO myocardium.    
 
Activators of AMPK   
As discussed in detail by (58) the AMPK kinases-AMPK signaling pathway is 
sensitive to alteration in AMP concentration at various levels including AMPK activity and 
phosphorylation and AMPKK phosphatase. Moreover the activation of AMPK by AMP is 
antagonized by high concentrations of ATP explaining the sensitivity of the system to both 
AMP and ATP. The sensitivity to AMP and ATP depends on the type of a and g isoform 
composing the heterotrimer (13); (48), (1). The estimation of the AMP (and ADP) 
concentration relevant for enzyme activation in a whole cell is not easy because their low 
concentrations prevent their NMR detection and the majority of the nucleotides are bound to 
intracellular compartments. The majority of the total AMP measured from a muscle extract, is 
bound in mitochondria and metabolically inactive (46). Alternatively free ADP and AMP 
concentrations are calculated from the NMR measured PCr ATP and H+ concentrations in the 
hypothesis of CK and AK equilibrium. Quasi metabolic steady state is acceptable in our 
protocol, first because both CK flux, about 8mM/s and AK flux (40) are at least 103 higher 
that the higher rate of ATP degradation (estimated from Fig 1in the ischemic a2-KO to 1.5 
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µM/s) and the Vmax of enzymes involved in AMP degradation (45), (21) and second because 
CK and AK had similar specific activities in both WT and KO (Table 3). Indeed the free 
[AMP] increase observed in our mouse heart perfused in low flow ischemia (from 1.5 to 7µM 
) is in the relevant range of AMPK activation found in vitro and in the perfused mouse heart 
(48), (16). Obviously lower level of AMPK phosphorylation in ischemia is expected from the 
60% decrease in total AMPK induced by a2 deletion. But in all our experimental conditions, 
in both a2-KO and WT, the phosphorylation of AMPK was related to the change in AMP to 
ATP ratio (compare Fig. 2 and Fig. 6 C). This holds true for LFI10. ILF5 exacerbated the 
AMP/ATP changes and further increased phosphorylation in both strains and after 
reperfusion. Under global ischemia, lower level of AMPK activation is also found in the same 
a2-KO heart but the accumulation of AMP in a2-KO was higher than in WT (58). Both 
results, might appear at first sight contradictory, but this discrepancy is due to the difference 
between global ischemia, a close system where degradation products accumulate in the cell, 
and low flow ischemia, an open system resulting in metabolic steady state where AMP 
hydrolysis and washout of degradation products can occur.  
Both PCr and the PCr to Cr ratio were early suspected to modulate AMPK activity 
(39), however more recent data evidence no direct regulation of AMPK or LKB1 by PCr (50). 
Thus the slightly higher PCr or PCr to ATP ratio of the a2-KO is most probably insignificant 
in the control of AMPK phosphorylation. However dual mechanisms operate in the ischemic 
heart that regulates AMPKK mediated phosphorylation and activation of AMPK. The AMP 
independent increase in AMPK activity in hypoxia (17) and the activation of AMPKK 
independent of an AMP increase or a change in LKB1 activity in the mildly ischemic rat heart 
(2) could contribute to the phosphorylation of the a1 subunit in the a2 KO.  
 
Is AMPK involved in cardiac protection or in cardiac injury?   
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The preservation of the ischemic and reperfusion function in the a2-KO, showing that 
a2 AMP isoform is not needed for the postischemic contractile recovery, is at major 
discrepancy with the results obtained in the a2 KD model (42). The a2-KD heart exhibits 
poor contractile function both during moderate low flow ischemia and reperfusion, associated 
with a major leakage of cytosolic enzymes and significant apoptotic response to I-R. A major 
difference between the two studies is the choice of substrates. We presented above our 
rationale for choosing pyruvate and glucose as substrate. The availability of long chain fatty 
acids in Russels’ study (42) most probably contributes to the severe ATP depletion and 
massive cytosolic enzyme leakage associated with a mild reduction in perfusion flow (to 30% 
compared to 5% in our protocol). Although a physiological substrate, long chain fatty acids in 
normoxia decrease cardiac efficiency, activate AMPK, and increase phosphorylation of 
acetyl-CoA carboxylase (8), (27), (11). It has been proposed that during reperfusion, sustained 
activation of AMPK and inactivation of ACC mediates the acceleration of fatty acid oxidation 
and the uncoupling of glucose oxidation and glycolysis (29), (30). Besides the difference in 
substrate, two crucial discrepancies between the studies are puzzling. Ischemia, as expected, 
phosphorylated a1-AMPK and stimulates glucose uptake in our model of a2–deletion (Fig. 6 
and (58)), as well as in the DN mutation (56) but surprisingly failed to do so in the KD 
mutation. The reasons for this lack of activation, which might participate in the severity of the 
ischemic insult, are not obvious but it is possible that the overexpression of inactive a subunit 
perturbs the heterotrimer a-ß-g association and the activation of AMPK. Before a definite 
conclusion about the beneficial or adverse role of a2 AMPK in ischemia can be drawn, it is 
indeed very important to understand if these opposite results are related to the available 
substrate, to the model of transgene insertion which might exert non specific effects, or to 
different adaptations often occurring in the various transgenic models.  
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FIGURE LEGENDS  
Figure 1:  Time dependent response to a low flow ischemia and reperfusion protocol: 
contractility and NMR measured phosphorus compounds  
Top panels: NMR measured parameters .Concentrations of PCr and ATP (in mM), ratio of 
PCr to ATP and pHi.  
Bottom panel: mechanical activity. End diastolic pressure, EDP in mmHg; Rate pressure 
product, RPP in 104.mmHg.beats.min-1 
C: control flow (WT, n=12, a2-KO, n=11); LFI10 for 30 min. (n= 9); LFI5 for 15 min, (n=6) 
R: reperfusion in control flow (n=6) ? : WT ? : a2-KO. Significant difference between a2-KO 
and WT *: p<0.05 (for clarity the difference with the control value is not shown, see result 
section) 
 
Figure 2  steady state of some  metabolites in low flow ischemia and reperfusion  
Steady state: average of the last two spectra in each perfusion condition in hearts of Fig1, 
empty bars = WT, filled bar = a2-KO. Sum of adenylates = ATP + ADP + AMP.   
Significant difference between WT and a2-KO: *:p< 0.05; **: p<0.01; ***: p<0.001. 
Significantly different from the respective control group $ p<0.05; $$: p<0.01; $$$: p<0.001. 
 
Figure 3  Creatine kinase function  
A- 31P NMR measured forward CK flux 
CK forward flux during metabolic steady state under control flow (c: n=11) and low flow 
ischemia (LFI10 n=9) in WT (empty bars) and a2-KO (filled bars). Significant difference 
between WT and a2-KO: *: p< 0.05. Significant difference with control group $: p<0.05; $$: 
p<0.01; $$$: p<0.001. 
B- Functional activity of myofibrillar MM-bound CK  
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Sensitivity of the rigor tension to ATP was similar in X100 triton fibers of a2-KO and WT 
hearts: half maximum rigor tension occurred at similar pATP50. The efficiency of MM-bound 
CK (arrow), estimated from the shift in the apparent sensitivity to MgATP induced by the 
addition of 12mM PCr, was similar in both strains (see Table 4 for mean data)  
 
Figure 4: 31P NMR estimation of the glucose transport and phosphorylation and its 
stimulation by low flow ischemia   
A-  Stacked plot of NMR spectra showing the accumulation of 2DG6P as a function of time in  
a representative WT (left panel) and a2-KO heart (right panel) perfused at control flow of 2.5 
mL.min-1. Spectrum a: control; spectrum b, c, d were acquired 2.5, 5, 7.5 min, respectively 
after infusion of 2-Deoxy-D-glucose (2DG= 5mM). Substrate: pyruvate 2mM in presence of 
external Pi 1mM, 5 min acquisition time for each spectrum  
 B- Rate of 2DG6P accumulation in control and LFI 
Left panel: average rate of 2DG6P accumulation was slower in a2-KO than in WT both in 
control and under LFI10. Significant difference between a2-KO and WT *: p< 0.05; **: 
p<0.01. Significantly different from control: $: p<0.05 
Right panel: stimulation of 2DG transport and phosphorylation by LFI10 was similar in a2-KO 
and WT. expressed as the fold increase in 2DG6P rate of accumulation induced by LFI10 for 
each individual heart  
C- Expression of glut 1 and glut4 protein   
Western Blot analysis. Empty bars WT n= 7, filled bar a2-KO, n= 7  
 
Figure 5: AMPK and its phosphorylation in low flow ischemia in WT and KO   
A- WB showing total AMPK protein and its phosphorylation at Thr172 in control condition 
and  low flow ischemia  (LFI10) in absence (left) and in presence of 2DG (right)  
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B- Total AMPK protein in WT (empty bar) and a2-KO (filled bar)   
C- Average level of phosphorylation of total AMPK in C: control (WT, n=4; a2-KO n=4), 
LFI10: 30 min of low flow ischemia (WT n=7, a2-KO n=7), R: 35 min after reperfusion (WT 
n=4, a2-KO n=3) and LFI-2DG 15 min of 2DG + LFI10 =15 min (WT n= 5, a2-KO n=6). 
Normalized unit: AMPK-P normalized to AMPK-P of a rat heart after 10 min of global 
ischemia.  
Significantly different from control $: p<0.05; $$ p<0.01; $$$ p<0.001 
Significant difference between a2-KO and WT *: p< 0.05; ** p<0.01; ***:p<0.001 
 
Figure 6 oxygen consumption and the economy of contraction  
A- Low flow ischemia, and reperfusion protocol. RPP (in 104.mmHg.beats.min-1) and oxygen 
consumption (in µmoleO2.min-1.gWW-1), EDP changes were similar to Fig. 1A (¢: WT, n=6; 
l: a2-KO, n=6) 
B- Response of a2-KO and WT hearts to a b-stimulation induced by increasing 
concentrations of isoprenaline ranging from 10-10M to 10-7M. Steady state values obtained 10 
minutes after the change in isoprenaline concentration ( p: WT, n=6 n: a2-KO, n=6). 
C- Energy cost of contraction estimated from the linear relationship between QO2 and RPP 
for both protocols. Data included both LFI and isoprenaline protocols Average linear 
regressions were described by y = 2.26 x + 0.91, r2= 0.9967 in WT and by y= 1.50x +1.43, r2= 
0.9907 in a2- KO (where y= QO2 and x= RPP). T test analysis (performed on the individual 
relationship of each heart) showed a significant difference between the slopes of WT and KO 
( n=12 for each WT and a2-KO, p<0.05) but no difference for the ordinate at origin .  
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Table 1 Comparison of the cardiac function of normoxic a2-AMPK KO and WT hearts 
 
Caracteristics of the animals 
 WT, n= 56 a2-KO, n= 60 
Age month 8.9 ± 0.5 8.1 ± 0.5 
Body weight g 36.5 ± 0.9 35.2 ± 0.7 
Heart weight g 0.29 ± 0.01 0.28 ± 0.01 
HW/BW mg. g-1 7.6 ± 0.2 7.9 ± 0.2  
 
 
Cardiac function of the isolated heart perfused at constant flow 
 WT, n=24 a2-KO, n=19 
LVDP, mmHg 71 ± 4 71 ± 4 
Heart rate, beats.min-1  319 ± 17 292 ± 16 
RPP, 104.mmHg.beats.min-1 2.1 ± 0.1 2.0 ± 0.1 
Coronary Pressure, mmHg.  103 ± 8 112 ± 9 
EDP, mmHg 8 ± 1 9 ± 1 
Hearts were perfused at a constant flow of 2.5mL.min-1 in presence of pyruvate 2mM and 
glucose 11mM as substrate. Measured parameters were: heart rate, LVDP (left ventricular 
developed pressure), EDP (end diastolic pressure), coronary pressure and RPP (the rate 
pressure product). Significantly different from WT *: p<0.05.  
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Table 2 Energetic parameters of the basal control WT and a2-AMPK KO heart 
 
 WT , n=12 a2-KO, n=11 
ATP, mMoles.l-1 8.6± 0. 3 8.4 ± 0. 2 
PCr, mMoles.l-1 16.2 ± 0.7 14.4 ±  0.6 
Pi, mMoles.l-1 4.0 ± 0.5 3.6 ± 0.4 
PCr/ATP 1.9 ± 0.1 1.7 ± 0.1 
pHi 7.09 ±0.02 7.08±0.01 
ADP, µMoles.l-1 59 ± 7 68 ± 6 
A ATP, kJ.M-1 -56.2 ± 0.4 -56.0 ± 0.5 
AMP, µMoles.l-1 0.48 ± 0.10 0.76 ± 0.22 
AMP/ATP * 105 0.56 ± 0.11 0.64 ± 0.08 
Glycogen, 
 µmol glucosyl unit.gFW-1 12.2 ± 0.8 5.5 ± 0.7 *** 
ATP, PCr, Pi  and pHi were measured from 31P NMR spectroscopy after 30 min 
equilibration in normoxic perfusate containing pyruvate  and glucose using the ATP measured 
biochemically as standard. Correction from partial saturation of NMR signal due to 
incomplete magnetization relaxation was applied. Free ADP, Free AMP and -A ATP the free 
energy of ATP hydrolysis were calculated using the equilibrium constant of CK and AK. No 
significant difference was found in any of the energetic parameters except for the glycogen 
content (measured in WT, n=4 and a2-KO n=5). 
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Table 3 Enzymatic activities   
 
 
Control Reperfusion 
 WT, n=3 a2-KO, n=3 WT, n=7 a2-KO, n=5 
Creatine kinase 507 ± 39 669 ± 47 273 ± 47$ 258 ± 39$ 
Adenylate kinase  370 ± 12 389 ± 9 116 ± 16$ 104 ± 9$ 
Citrate synthase  150 ± 17 133 ± 6 137 ± 10 140 ± 15 
LDH 203 ±19- 211± 15 118 ± 8$ 104 ± 9$ 
Data from freeze clamped hearts. Control obtained after 20 min of basal perfusion; 
Reperfusion: 35 min after LFI10 and 5 (hearts of Fig. 1). Activities are expressed in UI. g FW-1. 
$: significantly different from control p< 0.05. No significant difference between WT and a2-
KO for any variable.    
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Table 4 Intrinsic contractile properties of the myofilaments  
 
 WT n=9 a2-KO n=9 
Fiber diameter, µm  239±17 215±10 
 Ca activated force 
Resting force, mN.mm-2    3.8±0.6 4.0±0.7 
Active force, mN.mm-2    34.2±2.4 32.3±1.7 
pCa50 5.55±0.03 5.64 ±0.03 
nH 2.90±0.10 2.67±0.08 
 Rigor force 
pMgATP50 3.28 ±0.05 3.30±0.05 
pMgATP50+ PCr 5.03±0.03 4.98±0.05 
MM-CK efficacy  1.73±0.05 1.68±0.06 
 
pCa50 = -log 1/[Ca] is the concentration in Ca leading to half of the maximum active force. nH 
Hill coefficient. pMgATP50 and pMgATP50+PCr are the concentrations of MgATP needed to 
develop half of the rigor force (respectively in the absence and in the presence of PCr 12mM). 
MM-CK efficacy = ((pMgATP50 +PCr)-pMgATP50) is the shift in the apparent sensitivity to 
MgATP induced by CK activation 
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